<PAGE>

                                 UNITED STATES
                      SECURITIES AND EXCHANGE COMMISSION
                            Washington, D.C. 20549

                                 FORM 10-QSB/A

(Mark One)

[X]   QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
                   SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended           Commission File Number
---------------------------------------------------------------
    September 30, 2000                           0-11476


                               HEALTHWATCH, INC.
            ------------------------------------------------------
       (Exact Name of Small Business Issuer as Specified in Its Charter)

           Minnesota                                      84-0916792
    -------------------------                          -----------------
 (State or Other Jurisdiction of                       (I.R.S. Employer
  Incorporation or organization)                      Identification No.)


             1100 Johnson Ferry Road, Suite 670, Atlanta, GA 30342
             -----------------------------------------------------
                   (Address of Principal Executive Offices)

                                (404) 256-0083
                    -----------------------------------------
                (Issuer's Telephone Number, Including Area Code)

                                      N/A
                    --------------------------------------------
        (Former Name, Former Address and Former Fiscal Year, if Changed
                              Since Last Report)

Check whether the issuer: (1) filed all reports required to be filed by Section
13 or 15 (d) of the Exchange Act during the past 12 months (or for such shorter
period that the registrant was required to file such reports) and (2) has been
subject to such filing requirements for the past 90 days.

                        Yes X         No ______
                            ----

     Number of registrant's common shares outstanding at October 31, 2000
  2,142,751
-----------
           Transitional Small Business Disclosure Format (check one)
                         Yes ______   No X
                                        ---
<PAGE>

EXPLANATORY NOTE:

This amended quarterly report on Form 10-QSB for the quarter ended September 30,
2000 includes a restatement of the September 30, 2000 and 1999 financial
statements to (1) reflect the effects of a change in the amortization life of
the Company's intangible asset identified as the Merad Technology from ten years
to five years and (2) an adjustment to reflect the beneficial conversion feature
related to the Series P and Series D preferred stock.

We have made no further changes to the previously filed Form 10-QSB. All
information in this Form 10-QSB is as of September 30, 2000 and does not reflect
any subsequent information or events other than the aforementioned changes.
<PAGE>

                               HEALTHWATCH, INC.
                           CONSOLIDATED BALANCE SHEET
                                  (UNAUDITED)
                               SEPTEMBER 30, 2000

                                    PART I.
                             FINANCIAL INFORMATION

ITEM 1.   FINANCIAL STATEMENTS

<TABLE>
<CAPTION>
                                        ASSETS
<S>                                                                    <C>
Current Assets
        Cash                                                            $     63,317
        Accounts receivable, net of allowance for doubtful
           accounts of $17,692                                                51,466
        Inventory                                                             32,067
        Marketable securities                                              3,210,500
        Other current assets                                                 239,852
                                                                        ------------
                    Total current assets                                   3,597,202

        Investment in and advances to Halis, Inc.                          1,946,157
        Property and equipment, net                                           71,018
        Intangible assets, net of accumulated amortization
           of $401,738                                                       928,636
        Other assets                                                          39,926
                                                                        ------------
                    Total other assets                                     2,985,737
                                                                        ------------

                    Total assets                                        $  6,582,939
                                                                        ============
                              LIABILITIES AND SHAREHOLDERS' EQUITY

Current Liabilities
        Accounts payable                                                $    395,570
        Accrued expenses                                                     179,955
        Deferred revenue                                                       7,264
        Debentures payable                                                    25,000
                                                                        ------------

                    Total liabilities (all current)                          607,789
                                                                        ------------

Shareholders' Equity
        Cumulative preferred stock, 1,000,000 shares authorized,
          par value $.05 per share:
           Series A, 5,000 shares issued and outstanding                         250
           Series P, 66,886 shares issued and outstanding                      3,344
           Series C, 4,000 shares issued and outstanding                         200
           Series D, 74,130 shares issued and outstanding                      3,707
         Common stock, $.05 par value; 10,000,000 shares authorized,
           2,142,751 issued and outstanding                                  107,137
         Additional paid-in capital                                       34,146,106
         Accumulated deficit                                             (28,241,789)
         Accumulated other comprehensive loss, net unrealized
           investment losses                                                 (43,805)
                                                                        ------------
                    Total shareholders' equity                             5,975,150
                                                                        ------------
</TABLE>

                                       3
<PAGE>

     Total liabilities and shareholders' equity                      $ 6,582,939
                                                                     ===========

       (The accompanying notes are an integral part of these statements)

                                       4
<PAGE>

                               HEALTHWATCH, INC.
                     CONSOLIDATED STATEMENTS OF OPERATIONS
            FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2000 AND 1999
                                  (UNAUDITED)

                                                Three Months Ended September 30,
                                                        2000         1999
                                                --------------------------------

Sales                                               $   104,266    $ 151,703
Cost of sales                                            22,576       82,551
                                                    -----------    ---------
   Gross profit                                          81,690       69,152
                                                    -----------    ---------

Operating costs and expenses
   Selling, general and administrative                  915,340      263,590
   Depreciation and amortization                         57,709      110,494
   Research and development                              38,480       37,190
                                                    -----------    ---------

Total operating costs and expenses                    1,011,529      411,274
                                                    -----------    ---------

Operating loss                                         (929,839)    (342,122)
                                                    -----------    ---------

Other income (expense)
   Loss from investment in Halis, Inc.                 (118,660)     (96,102)
   Realized gain on sale of marketable securities           150            -
   Interest income                                       58,104            -
   Interest expense                                      (3,614)     (16,458)
                                                    -----------    ---------

          Total other income (expense)                  (64,020)    (112,560)
                                                    -----------    ---------


Net loss                                            $  (993,859)   $(454,682)
                                                    ===========    =========


Basic and diluted net loss per common share:
   Net Loss                                         $  (993,859)   $(454,682)
   Less preferred stock dividends (undeclared)          223,521       67,261
   Less amortization of beneficial conversion
   option on Series D and Series P preferred stock    1,495,845       78,257
                                                    -----------    ---------
   Net loss available to common shareholders        $(2,713,225)   $(600,200)
                                                    ===========    =========

Net loss per common share, basic and diluted        $     (1.27)   $   (0.72)
                                                    ===========    =========

Weighted average number of shares outstanding         2,142,751      835,991*
                                                    ===========    =========


*Adjusted for December 1999 1 for 5 stock split


      (The accompanying notes are an integral part of these statements.)

                                       5
<PAGE>

                               HEALTHWATCH, INC.
                     CONSOLIDATED STATEMENTS OF CASH FLOWS
                 FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2000
                                   AND 1999
                                  (UNAUDITED)

<TABLE>
<CAPTION>
                                                           Three Months Ended September 30,
                                                                   2000         1999
                                                           --------------------------------
<S>                                                        <C>               <C>
CASH FLOWS FROM OPERATING ACTIVITIES:
        Net loss                                                $(993,859)   $(454,682)
        Adjustments to reconcile net loss to net cash
         provided by (used in) operating activities:
          Depreciation and amortization                            57,709      110,494
          Provision for bad debt                                        -       (6,399)
          Loss from investment in Halis, Inc.                     118,660       96,102
          Issuance of stock for services                                -       50,002
          Gain on sale of marketable securities                      (150)           -

        Decrease (increase) in assets:
          Accounts receivable                                     (16,926)      74,297
          Inventory                                                 3,410        2,639
          Other current assets                                     26,441        6,198
          Other assets                                             (1,366)       3,400

        Increase (decrease) in liabilities:
          Accounts payable                                        118,206        2,172
          Accrued expenses                                        (49,859)     (35,102)
          Deferred revenue                                         (1,225)       4,389
                                                                ---------    ---------

               Net cash used in operating activities             (738,959)    (146,490)
                                                                ---------    ---------

CASH FLOWS FROM INVESTING ACTIVITIES:
        Purchase of property & equipment                          (57,680)           -
        Proceeds from sale of marketable securities               794,745            -
        Purchase of intangible assets, capitalized MERAD
          Technology costs                                        (97,723)           -
        Decrease in due from Halis, Inc.                          146,670       95,342
                                                                ---------    ---------

             Net cash provided by investing activities            786,012       95,342
                                                                ---------    ---------

CASH FLOWS FROM FINANCING ACTIVITIES:
        Net proceeds from issuance of common stock                      -       50,000
                                                                ---------    ---------

          Net cash provided by financing activities                     -       50,000
                                                                ---------    ---------

          Increase (decrease) in cash                              47,053       (1,148)
          Cash - beginning of period                               16,264       21,746
                                                                ---------    ---------

           Cash - end of period                                 $  63,317    $  20,598
                                                                =========    =========

</TABLE>


       (The accompanying notes are an integral part of these statements)

                                       6
<PAGE>

                               HEALTHWATCH, INC.
                  NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
                 FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2000
                                  (UNAUDITED)

PRINCIPLES OF PRESENTATION

The accompanying unaudited financial statements have been prepared in accordance
with generally accepted accounting principles for interim financial information
and with the instructions to Form 10-QSB. Accordingly, they do not include all
of the information and footnotes required by generally accepted accounting
principles for complete financial statements. In the opinion of management, all
adjustments (consisting of normal recurring accruals) necessary for a fair
presentation of the Company's financial position as of September 30, 2000, and
its results of operations and cash flows for the three months then ended have
been included. However, operating results for the interim periods noted are not
necessary indicative of the results that may be expected for the year ending
June 30, 2001. This report should be read in conjunction with the Company's
Financial Statements and Notes thereto contained in the Company's annual report
on Form 10-KSB for the year ended June 30, 2000.

MANAGEMENT'S OPERATING PLANS

HealthWatch has been in business for over a decade, but its information
technology business is still relatively new. Prior to fiscal year 1998,
HealthWatch was primarily in the business of manufacturing and selling medical
devices and related supplies. In 1997, management decided to phase out of the
medical device business and focus its energies on developing an information
technology business. The Company still provides maintenance support to a number
of customers who purchased medical devices in the past.

On October 1, 1998, as part of the transformation, the Company acquired Paul
Harrison Enterprises, Inc. ("PHE"). PHE owned the Merad Technology, a
sophisticated virtual software application utility that utilizes an advanced
multi-media object and relational database which creates knowledge objects that
can be used and reused in a virtually unlimited number of combinations to
provide efficient applications that can be accessed and processed in both an
Internet and Intranet environment (the "Merad Technology"). The acquisition of
PHE, which was a significant shareholder of Halis, Inc. ("Halis"), also
increased the Company's ownership of the common stock of Halis, a healthcare IT
company, to approximately 19% of Halis' outstanding shares of common stock. On
January 29, 1999, the Company acquired an additional 1,824,645 shares of Halis'
common stock by converting $157,741 owed by Halis to the Company pursuant to a
debenture, bringing its ownership interest in Halis to approximately 22% and
allowed it to account for its investment in Halis under the equity method of
accounting.

Halis, based in Atlanta, Georgia, supplies information technology and services
focused on the healthcare industry. Utilizing advanced healthcare models and
information technology, Halis has developed the HES System, which incorporates
the Merad Technology, a single system which integrates all of the major
functions needed by clinics, hospitals, healthcare practices, payors, long-term
care facilities, laboratories, pharmacies and home healthcare facilities.

                                       7
<PAGE>

As part of the Company's business plan, management is in the process of
identifying strategic business partners and acquisition candidates in the
systems integration and support area that will enhance the Company's ability to
develop its information management business. The first such candidate is Halis.
On June 29, 2000, the Company and Halis executed a definitive merger agreement
pursuant to which Halis will merge with and into a wholly owned subsidiary of
the Company. Management anticipates that the merger will close during January
2001. The merger with Halis is especially attractive to the Company because of
the HES System and the long term operating relationship and common management
between the two companies (Paul W. Harrison is President, Chief Executive
Officer and Chairman of the Board of both companies). HealthWatch and Halis have
operated under a Business Collaboration Agreement (the "Collaboration
Agreement") since October 1997. The Collaboration Agreement provides, among
other things, for revenue sharing from sales of each company's products based on
a 60/40 split (i.e., the selling company would receive 60% of the sales price
received and the company that owns the technology would receive 40% of the sales
price received). Furthermore, HealthWatch is obligated to pay Halis a
collaboration fee of $50,000 per month, which is applied as a credit against any
revenue sharing amount that is due to Halis. Halis is obligated to provide
support to HealthWatch for the Halis software products, provide reasonable
product enhancement as part of product release updates and cooperate with
HealthWatch in regard to product enhancement requests. HealthWatch may terminate
the $50,000 monthly collaboration fee payable to Halis on or after October 1,
2001, under certain terms and conditions. The Collaboration Agreement terminates
on September 20, 2005 and provides for automatic one-year extensions unless
terminated with a ninety-day notice by either party. HealthWatch and Halis also
share office space in Atlanta, Georgia and administrative support under a cost
sharing arrangement.

The Halis merger agreement provides for the issuance of shares of HealthWatch
common stock to Halis shareholders in exchange for all outstanding stock of
Halis. The holder of each share of Halis common stock will be entitled to
receive .050 shares of HealthWatch's common stock (i.e., an exchange ratio of
one share of HealthWatch common stock for twenty shares of Halis common stock).
Under the terms of the merger agreement, the Company will issue approximately
2,300,000 shares of its common stock to Halis stockholders, excluding
HealthWatch. Completion of the merger is conditioned upon certain events such as
approval by both companies' shareholders, obtaining any required governmental
and regulatory approvals and the absence of any material adverse changes in
Halis' business or operations.


NET LOSS PER SHARE

The net loss per share was computed based on the weighted average number of
shares outstanding during the periods without taking into effect outstanding
options and warrants, convertible debt and convertible preferred stock.


DEBENTURES PAYABLE

As of September 30, 2000, the Company had outstanding debentures with principal
totaling $25,000. The debentures accrue interest at a annual rate of 10%,
payable quarterly. The debentures matured on March 1, 1998, and are currently in
default as to the payment of principal

                                       8
<PAGE>

and past due interest. The debentures, including unpaid accrued interest, could
be converted, at the option of the holder, into shares of the Company's common
stock. As of September 30, 2000, $7,918 in accrued but unpaid interest was
outstanding on the debentures. The Company is attempting to reach an agreement
with the remaining debenture holder in an effort to resolve the amounts
outstanding or otherwise bring the debentures out of their default status.


INVESTMENT IN HALIS COMMON STOCK

As of September 30, 2000, the Company held 15,763,655 shares of the common stock
of Halis, representing approximately 25% of the total outstanding shares. The
Company does not hold the Halis shares for trading purposes, but rather holds
them for long-term investment purposes. Thus, as required by generally accepted
accounting principles, the Company accounts for its investment in Halis under
the equity method of accounting, thereby reflecting its portion of Halis'
earnings or losses in the Company's statement of operations with a corollary
adjustment to its investment account. The Company's share of Halis' net loss for
the three month period ended September 30, 2000 was $72,527.

At September 30, 2000, the carrying value of the Company's investment in Halis
exceeded the aggregate value, based on the quoted market price, by $915,436. In
management's opinion, the decline is temporary in nature, and therefore, no
adjustment was made to reduce the carrying value of the Halis investment.
Additionally, the carrying value of the Halis investment under the equity method
exceeded the equity in the underlying assets of Halis at the date of conversion
to the equity method by $1,845,329. This excess is being amortized on the
straight line method over 10 years, or $184,533 per year.


RESTATEMENTS

     The September 30, 2000 financial statements have been restated to reflect
an adjustment to the June 30, 2000 financial statements for interest expense of
$419,551 from the issuance of warrants in connection with short-term financing.
The effect of the adjustment increased additional paid-in capital and increased
accumulated deficit by $419,551 at September 30, 2000.

     The September 30, 2000 financial statements have been restated to reflect
an adjustment to the June 30, 2000 and 1999 financial statements to reflect the
beneficial conversion feature related to the Series P and Series D preferred
stock. The effect of the adjustment increased additional paid-in capital and
increased accumulated deficit by $1,884,700 at September 30, 2000. In addition,
additional paid-in capital and accumulated deficit increased by $1,495,845 as a
result of the amortization of the beneficial conversion feature for the three
months ended September 30, 2000. The effect of the adjustments increased the
loss available to common shareholders by $1,495,845 and $78,257 for the three
months ended September 30, 2000 and 1999, and increased the loss per common
share by $.71 and $.10 for the three months ended September 30, 2000 and 1999,
respectively.

     The September 30, 2000 and 1999 financial statements have been restated to

                                       9
<PAGE>

reflect the effects of a change in the amortization life of the Company's
intangible asset identified as the Merad Technology from ten years to five
years. The effect of the adjustment decreased intangible assets by $202,658 at
September 30, 2000, increased the loss available to common shareholders by
$30,614 and $25,284 for the three months ended September 30, 2000 and 1999,
respectively, and increased the net loss per common share by $.01 and $.03 for
the three months ended September 30, 2000 and 1999, respectively.


FORWARD-LOOKING STATEMENTS

This Form 10-QSB contains certain forward-looking statements within the meaning
of Section 27A of the Securities Act and Section 21E of the Securities and
Exchange Act of 1934, as amended, which are intended to be covered by the safe
harbors created thereby. These statements include the plans and objectives of
the Company for future operations. The forward-looking statements included
herein are based on current expectations that involve numerous risks and
uncertainties. The Company's plans and objectives are based on the assumption
that the Company's entry into the healthcare industry will be successful, that
competitive conditions within the healthcare industry will not change materially
or adversely, and that there will be no material adverse change in the Company's
operations or business. Assumptions relating to the foregoing involve judgments
with respect to, among other things, future economic, competitive and market
conditions, as well as future business decisions, all of which are difficult or
impossible to predict accurately and many of which are beyond the control of the
Company. Although the Company believes that the assumptions underlying the
forward-looking statements included herein are reasonable, the inclusion of such
information should not be regarded as a representation by the Company, or any
other person, that the objectives and plans of the Company will be achieved.


ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION

During fiscal 2001, the Company continued efforts to develop proprietary
technology utilizing MERAD and to market, as a reseller, Halis' Healthcare
Enterprise System to the Company's customers. The Company expects to continue to
expand its collaborative efforts with Halis and to expand its efforts to market
the Halis Healthcare Enterprise System. As such, on June 29, 2000, the board of
directors of HealthWatch and Halis executed an agreement and plan of merger
whereby Halis would become a wholly owned subsidiary of HealthWatch. Management
of both companies believe that the combined company's breadth of technology,
products, management and operational experience and financial resources should
enable it to respond more quickly and effectively to technological change,
intensifying competition, increasing consolidation and evolving market demands.
Moreover, management of HealthWatch and Halis believe that the combined company
could achieve operating synergies through cross marketing of each company's
products and services, as well as possible cost savings related to more
efficient administrative and support functions of the combined companies.

The Company has incurred significant operating losses during the past several
years and at September 30, 2000 had an accumulated deficit of $28,241,789. The
Company has acquired additional equity capital to sustain operations and to
continue its business development efforts.

                                      10
<PAGE>

Total assets at September 30, 2000 were $6,582,939, representing a decrease of
$857,007 from June 30, 2000. Marketable securities and investment in and
advances to Halis represented $725,000 and $265,330, respectively, of the
decrease. The decrease in investment in and advances to Halis is attributable to
a decrease in the investment in Halis of $118,660 and a decrease in the Due from
Halis account of $146,670. The decrease in marketable securities is the result
of sales of securities for the purpose of funding current operating expenses and
to payoff certain accrued liabilities. The decreases were offset by increases in
cash, property and equipment, and intangible assets of $47,053, $57,680 and
$97,857, respectively, net of depreciation and amortization of $57,709.

Current liabilities increased by $67,255 from $540,534 at June 30, 2000 to
$607,789 at September 30, 2000. The increase is primarily attributable to an
increase in accounts payable of $118,206 and a decrease in accrued expenses of
$49,724.

Shareholders' equity decreased from $6,899,412 at June 30, 2000 to $5,975,150 at
September 30, 2000, a decrease of $924,262. This decrease is attributable to a
net loss for the three month period of $993,859 with an offsetting decrease in
accumulated other comprehensive loss, net unrealized investment losses of
$69,595.

RESULTS OF OPERATIONS

Revenues for the three month period ended September 30, 2000 declined by
$47,437, or 31.3%, as compared to the same period in 1999. The decline in
revenue is primarily due to the Company's continued shift from a product driven
supply company to a software information technology company. During the three
month period, product sales were minimal and almost all of the revenues
generated were the result of supplies, service and repair work. The Company
recognized income of $270 from Halis for the three month period ended September
30, 2000, compared to $8,100 in the similar period in 1999, under its business
collaboration agreement with Halis for sales of the HES System. Such amounts are
included in product sales.

Gross profit was 78.3% for the three month period ended September 30, 2000, as
compared to 45.6% for the same period in 1999. The increase in gross profit
percentage is due primarily to previous write-downs of slow moving inventory to
lower of cost or market and a general shift from product sales to service and
support.

Selling, general and administrative expenses increased by $651,750 for the three
month period ended September 30, 2000 from the comparable 1999 period. The
increase is due primarily to increased consulting and professional fees
resulting from the Company's shift from a product supply company to a software
information technology company, the cost associated with implementing the
Company's business plan and SEC and Nasdaq compliance reporting.

Depreciation and amortization decreased by $52,785 for the three months ended
September 30, 2000, as compared to the same period in 1999. The decrease is the
result of reduced amortization expense due to a loss from impairment of
intangible assets in fiscal 2000.

Losses from investment in Halis increased from $96,102 for the three month
period ended September 30, 1999 to $118,660 for the three month period ended
September 30, 2000. The

                                      11
<PAGE>

losses represent the Company's pro-rata share of Halis' net loss during the
three month periods ending September 30, 1999 and 2000, plus charges totaling
$46,133 for amortization of the excess carrying value of the Halis investment
over the equity in the underlying net assets of Halis.

Interest income of $58,104 for the three months ended September 30, 2000 is
related to the investment in marketable debt securities. Interest expense
decreased to $3,614 for the three months ended September 30, 2000 compared to
$16,458 for the similar period in 1999 due to the conversion of interest bearing
debentures into common stock during fiscal 2000.

The Company has discontinued the sale of its medical products (i.e., the MVL and
Pacer products) and will continue to focus on its information technology
business, in addition to the supplies and technical support offered to its
customer base relating to its medical products still in service. As a result of
the restructuring during fiscal 1999 and 2000, the Company has improved its
financial condition and is now capable of devoting its resources to the
marketing and distribution of the HES product.

LIQUIDITY AND CAPITAL RESOURCES

At September 30, 2000, the Company had $63,317 of cash and $3,210,500 of
investments in marketable securities. During the three month period ended
September 30, 2000, operating activities consumed $738,959 of cash compared to
$146,490 for the same period in 1999. The increase in cash used in operations
for the three month period ended September 30, 2000 is primarily the result of
increased consulting and professional fees.

Investing activities provided $786,012 and $95,342 of cash during the three
month period ending September 30, 2000 and 1999, respectively. The increase is
primarily attributable to the sale of marketable securities and a decrease in
investment in and advances to Halis of $794,745 and $146,670, respectively. The
increases were offset by the purchase of property and equipment and capitalized
MERAD technology costs of $57,680 and $97,723, respectively.

Due to the Company's history of operating losses, it has been required to raise
additional equity capital to fund its operations. The capital raised during
fiscal 2000 was sufficient to allow the Company to fund current operating
expenses and to payoff certain prior period accrued liabilities without raising
any monies through financing activities during the three month period ending
September 30, 2000.

Due to the Company's success in raising additional capital during fiscal 2000
through the private placement of its securities, management has begun to
implement its business plan, which includes securing the additional personnel
needed to manage the marketing and advertising of its products, additional
investment in research and development and the acquisition of strategic partners
needed to grow the Company's revenues. During the quarter ended March 31, 2000,
HealthWatch hired a Chief Operating Officer with an expertise in the healthcare
information technology industry to assist the Company's marketing and
development of its products. The Company has also recently hired a Chief
Financial Officer.


                                   PART II.
                               OTHER INFORMATION

                                      12
<PAGE>

ITEM 2. CHANGES IN SECURITIES AND USE OF PROCEEDS

There were no securities issued during the three month period ended September
30, 2000.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

On March 1, 1998, $580,000 principal amount of the Company's 10% Secured
Convertible Debentures ("Debentures") were due and payable. The Company was
unable to pay the Debentures in accordance with their terms and the Company
obtained no further extension of the maturity date from the holders. During
fiscal 1999, $100,000 in principal of the Debentures was paid to the holders
thereof. The Debentures are convertible by the holders thereof into shares of
common stock. In January and February 2000, the Debenture holders converted
$455,000 of their Debentures and related accrued interest of $139,357 into
316,990 shares of common stock of the Company. As of September 30, 2000, only
$25,000 of the Debentures remain outstanding.


ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

The Company's Annual Meeting was held on July 14, 2000 for the purpose of (i)
electing six directors to the Company's board of directors and (ii) approving
the HealthWatch, Inc. 2000 Stock Option Plan. All director nominees were
elected. The voting tabulation was as follows: Paul W. Harrison, David M.
Engert, Robert Tucker and John R. Prufeta: 2,711,334 votes for; 46 votes
against; and 5,161 abstained. The Series C 8% Convertible Preferred Stockholders
elected Sheldon Misher to the board of directors as their designee. The voting
tabulation was as follows: 2,250 votes for; 0 votes against; and 0 votes
abstained. The Series D 8% Convertible Preferred Stockholders elected Robert
Priddy to the board of directors as their designee. The voting tabulation was as
follows: 37,630 votes for; 0 votes against; and 0 votes abstained. At that
meeting, in addition to the election of directors, the shareholders voted upon a
proposal to adopt the HealthWatch, Inc. 2000 Stock Option Plan. A total of
1,600,622 shares were voted in favor of the proposal, 19,974 shares were voted
against the proposal and 1,681 shares abstained from voting on the proposal. As
such, the HealthWatch, Inc. 2000 Stock Option Plan was adopted. There were no
other actions taken at the Annual Meeting.


ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K

(a)  EXHIBITS. The following exhibits are filed with or incorporated by
     reference into this report:
 2.1      Agreement and Plan of Merger by and among Halis, Inc., HealthWatch
          Merger Sub, Inc. and HealthWatch, Inc. dated as of June 29, 2000 (1).
 2.2      Amendment to the Agreement and Plan of Merger dated as of September
          29, 2000 (1).
 2.3      Letter of Intent between HealthWatch, Inc. and Halis, Inc. dated March
          8, 2000 (1).
 2.4      Amendment to the Financing Option between HealthWatch, Inc. and Halis,
          Inc. dated July 28, 2000 (1).

                                      13
<PAGE>

 3.1      Articles of Incorporation of HealthWatch, Inc., dated June 10, 1983
          (1).
 3.2      Certificate of Amendment of Articles of Incorporation of HealthWatch,
          Inc., dated October 20, 1987(1)
 3.3      Articles of Amendment of Articles of Incorporation of HealthWatch,
          Inc., dated December 5, 1989 (1).
 3.4      Articles of Amendment of Articles of Incorporation of HealthWatch,
          Inc., dated December 8, 1999 (1).
 3.5      Bylaws of HealthWatch, Inc. (1).
 3.13     Certification of Designation, Preferences, Rights and Limitations of
          the 6% Series A Convertible Preferred Stock of HealthWatch, Inc. dated
          June 9, 1998 (1).
 3.14     Amended and Restated Certification of Designation, Preferences, Rights
          and Limitations of the Series P Preferred Stock of HealthWatch, Inc.
          dated March 22, 2000 (1).
 3.15     Certification of Designation, Preferences, Rights and Limitations of
          the Series C 8% Convertible Preferred Stock of HealthWatch, Inc. dated
          March 20, 2000 (1).
 3.16     Certification of Designation, Preferences, Rights and Limitations of
          the Series D 8% Convertible Preferred Stock of HealthWatch, Inc. dated
          March 20, 2000 (1).
 4.1      Specimen form of the Company's Common Stock certificate (2)
 4.8      Subscription and Purchase Agreement dated as of the 14th day of August
          1992 between the Company and the Purchasers of the Company's 10%
          convertible senior debentures due 1997 (including as an appendix
          thereto the form of the debenture certificate) (3)
10.1      Business Collaboration Agreement dated as of October 10, 1997 between
          HealthWatch, Inc. and Halis, Inc. (1)
10.6      Form of Warrant Certificate of HealthWatch, Inc. (1)
10.8      Amended and Restated Agency Agreement between Commonwealth Associates,
          L.P. and HealthWatch, Inc. dated February 7, 2000 (1).
10.9      HealthWatch, Inc. 2000 Stock Option Plan, adopted as of May 8, 2000,
          approved by HealthWatch stockholders July 14 2000 (1).
10.10     Form of Stock Option Agreement  (1).
10.11     Amendment to the Business Collaboration Agreement dated September 20,
          2000 between Halis, Inc. and HealthWatch, Inc. (1)
10.12     Finders Agreement between HealthWatch, Inc. and Commonwealth
          Associates, L.P., dated March 21, 2000 (1)
21.1      Subsidiaries of HealthWatch, Inc. (1).
27.1      Financial Data Schedule (EDGAR filing only) (1)


(b)  REPORTS ON FORM 8-K. The following reports on Form 8-K were filed during
     the quarter ended September 30, 2000.

     None.
_________________________

(1)  Incorporated herein by reference to the Company's Registration Statement on
     Form S-4, filed on October 24, 2000 ( File No. 333-48546).
(2)  Incorporated herein by reference to Registration Statement on Form S-18
     (File No. 2-85688D).

                                      14
<PAGE>

(3)  Incorporated herein by reference to Registration Statement on Form SB-2
     (File No. 33-73462).

                                      15
<PAGE>

                                  SIGNATURES

     In accordance with the Exchange Act, the registrant caused this report to
be signed by the undersigned, thereunto duly authorized.

                                        HEALTHWATCH, INC.

Date: April 23, 2001                    /s/ Paul W. Harrison
                                        --------------------
                                         Paul W. Harrison
                                                 Chairman, President and Chief
                                         Executive Officer

Date: April 23, 2001                    /s/ Thomas C. Ridenour
                                        ----------------------
                                        Chief Financial Officer and Principal
                                        Accounting Officer
<PAGE>

                                 EXHIBIT INDEX

Number             Description
------             -----------

 2.1     Agreement and Plan of Merger by and among Halis, Inc., HealthWatch
         Merger Sub, Inc. and HealthWatch, Inc. dated as of June 29, 2000 (1).
 2.2     Amendment to the Agreement and Plan of Merger dated as of September 29,
         2000 (1).
 2.3     Letter of Intent between HealthWatch, Inc. and Halis, Inc. dated March
         8, 2000 (1).
 2.4     Amendment to the Financing Option between HealthWatch, Inc. and Halis,
         Inc. dated July 28, 2000 (1).
 3.1     Articles of Incorporation of HealthWatch, Inc., dated June 10, 1983
         (1).
 3.2     Certificate of Amendment of Articles of Incorporation of HealthWatch,
         Inc., dated October 20, 1987(1)
 3.3     Articles of Amendment of Articles of Incorporation of HealthWatch,
         Inc., dated December 5, 1989 (1).
 3.4     Articles of Amendment of Articles of Incorporation of HealthWatch,
         Inc., dated December 8, 1999 (1).
 3.5     Bylaws of HealthWatch, Inc. (1).
 3.13    Certification of Designation, Preferences, Rights and Limitations of
         the 6% Series A Convertible Preferred Stock of HealthWatch, Inc. dated
         June 9, 1998 (1).
 3.14    Amended and Restated Certification of Designation, Preferences, Rights
         and Limitations of the Series P Preferred Stock of HealthWatch, Inc.
         dated March 22, 2000 (1).
 3.15    Certification of Designation, Preferences, Rights and Limitations of
         the Series C 8% Convertible Preferred Stock of HealthWatch, Inc. dated
         March 20, 2000 (1).
 3.16    Certification of Designation, Preferences, Rights and Limitations of
         the Series D 8% Convertible Preferred Stock of HealthWatch, Inc. dated
         March 20, 2000 (1).
 4.1     Specimen form of the Company's Common Stock certificate (2)
 4.8     Subscription and Purchase Agreement dated as of the 14th day of August
         1992 between the Company and the Purchasers of the Company's 10%
         convertible senior debentures due 1997 (including as an appendix
         thereto the form of the debenture certificate) (3)
10.1     Business Collaboration Agreement dated as of October 10, 1997 between
         HealthWatch, Inc. and Halis, Inc. (1)
10.6     Form of Warrant Certificate of HealthWatch, Inc. (1)
10.8     Amended and Restated Agency Agreement between Commonwealth Associates,
         L.P. and HealthWatch, Inc. dated February 7, 2000 (1).
10.9     HealthWatch, Inc. 2000 Stock Option Plan, adopted as of May 8, 2000,
         approved by HealthWatch stockholders July 14 2000 (1).
10.10    Form of Stock Option Agreement  (1).
10.11    Amendment to the Business Collaboration Agreement dated September 20,
         2000 between Halis, Inc. and HealthWatch, Inc. (1)
10.12    Finders Agreement between HealthWatch, Inc. and Commonwealth
         Associates, L.P., dated March 21, 2000 (1)
21.1     Subsidiaries of HealthWatch, Inc. (1)
27.1     Financial Data Schedule (EDGAR filing only) (1).
________________________

(1)  Incorporated herein by reference to the Company's Registration Statement on
     Form S-4,
<PAGE>

     filed on October 24, 2000 ( File No. 333-48546).
(2)  Incorporated herein by reference to Registration Statement on Form S-18
     (File No. 2-85688D).
(3)  Incorporated herein by reference to Registration Statement on Form SB-2
     (File No. 33-73462).